A development is expected in the coming days on the proposed ban on private production of Oxytocin, used to prevent excessive bleeding during childbirth. Due to the apparent misuse and abuse of the drug, the Health Ministry sought to ban private producers from making and marketing the drug it in the country.
And to meet local supplies, the Centre appointed Karnataka Antibiotics & Pharmaceuticals Ltd (KAPL). However, as doctors cautioned that the move could adversely affect hospital supplies, the private ban was deferred. Subsequently, private producers of the drug approached the Delhi High Court. Presently, the HC stay on the private ban stands up to December 15. Doctors, private producers of the drug and government will be keenly watching what happens next.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.